Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis

2021年10月30日 00:26:46

打印 放大 缩小

The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA).

“GPP is a rare, life-threatening neutrophilic skin disease characterized by painful, sterile pus-filled blisters, that can suddenly appear over the body,” said Dr. Janine Lamar, Global Spesolimab Lead at Boehringer Ingelheim. “Despite its name, GPP is very different to the more common plaque psoriasis. With no approved treatments in the EU for GPP flares, acceptance of the application for review of spesolimab brings us one step closer to providing a targeted treatment for people with this distressing, unpredictable and painful skin condition.”

GPP is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).1,2,3 The inflammation can also affect other parts of the body and can lead to infections or other organ complications that may be life-threatening.

There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life4 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure, sepsis and even death.5

The marketing authorization application was based on the 12 week Effisayil-1 trial; a multi-center, double-blind, randomized, placebo-controlled trial that evaluated efficacy, safety, and tolerability of spesolimab (single dose 900 mg spesolimab i.v., with the option of a 2nd dose if symptoms persisted on Day 8) in patients experiencing a GPP flare.6 The study demonstrated superiority over placebo in pustular clearance after one week of treatment.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab

责任编辑:admin

相关阅读

搜狐网友:冷眸2  Cruel
评论:女人最恨的男人是陈世美;男人最喜欢的女人是潘金莲。

凤凰网友:俄怎会放得下
评论:好的文字是这样的:你写得不动声色,我看得肝肠寸断

其它网友:私欲° 7/m
评论:人之初,性本善,不写作业是好汉

网易网友:蠢蠢欲动 Einson
评论:我妈就生了这么一个限量版的我,你看着办吧Q_Q

天涯网友:冷笑你的无知
评论:这么不要脸,这么没心没肺,你的体重应该会很轻吧

百度网友:▲ 难舍 4hold〃
评论:好的爱情,战得胜时间,抵得住流年,经得起离别,受得住想念。

腾讯网友:迷途不知歸返
评论:婚外情可以是个浪漫的故事,但离婚则是一次惨痛的事故。

天猫网友:拥抱着还寂寞
评论:> 有人争取,就会有人失去

本网网友:念成疾 crize
评论:做女孩一定要经的起谎言,爱的起敷衍,忍的了欺骗,忘得了诺言,放的下一切,最后用笑来伪装你的泪眼!

淘宝网友:zore/. 极乐
评论:不是上午不想玩电脑,因为一起床就已经是中午了